Moleculin Biotech
MBRX
6 hedge funds and large institutions have $918K invested in Moleculin Biotech in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5,732% more capital inflows, than outflows
Capital inflows: $1.05M | Capital outflows: $18K
500% more funds holding
Funds holding: 1 → 6 (+5)
4.17% more ownership
Funds ownership: 0.77% → 4.95% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$420K |
| 2 |
Virtu KCG Holdings
New York
|
+$350K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$140K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$70K |
| 5 |
Two Sigma Securities
New York
|
+$70K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$17K |
| 2 |
Next Financial Group
Houston,
Texas
|
-$1K |
MBRX Hedge Fund Activity: Q1 2017 in Review
6 of the 4,035 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2017, worth a combined $918K — up 331% from $213K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MBRX positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $420K. The largest seller was Citigroup, cutting an estimated $17K.
- 6 institutional investors held Moleculin Biotech (MBRX) as of Q1 2017, up from 1 in Q4 2016.
- Funds reported $918K of Moleculin Biotech stock for Q1 2017, up 331% quarter-over-quarter.
- 5 funds opened new Moleculin Biotech positions in Q1 2017 and 0 closed out, a net change of +5 holders.
- The largest Moleculin Biotech buyer in Q1 2017 was Vanguard Group, an estimated $420K added.
- The largest Moleculin Biotech seller in Q1 2017 was Citigroup, an estimated $17K sold.
Based on aggregated 13F filings for Q1 2017.